What Explains the 5.85% Premarket Decline for bioAffinity (NASDAQ:BIAF) on Oct 9?

Vinay Lochav

09 October 2026 11:46 PM AEDT

What Explains the 5.85% Premarket Decline for bioAffinity (NASDAQ:BIAF) on Oct 9?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Takeaways

bioAffinity Technologies (NASDAQ:BIAF) fell 5.85% in premarket activity on October 9, 2026 on a displayed price of USD 5.64, the October 8 close after an 8.44% fall that day.
The probable catalyst is an October 8 disclosure of a roughly USD 4 million registered direct financing and concurrent private placement, with shares priced at USD 6.122, according to released Business news.
The USD 6.122 Offer Price was approximately 8.5% above the USD 5.64 close, simple arithmetic, so the financing was priced at a premium to the closing price but the stock still declined.
The company stated CyPath Lung sales expanded more than 100% through the third quarter of 2026, yet full-year 2025 Revenue of USD 6.16 million declined from USD 9.36 million.

Factors Behind bioAffinity’s Share-Price Move

bioAffinity Technologies (NASDAQ:BIAF) was indicated to be down 5.85% in the October 9, 2026 premarket session on the screener, on a displayed price of USD 5.64 and pre-market Volume of 13,667 shares. The screener tags an other event. A released headline list demonstrates that on October 8 the issuer announced a registered direct offering of approximately USD 4 million with shares sold at USD 6.122 and a concurrent private Placement priced at the market under Nasdaq rules, with WallachBeth Capital named in a related headline. The same list demonstrates a Volatility halt that day and an 8.44% fall to the close. The particulars were taken from one data page and should be verified against a primary source against the issuer filing.

Business, Sales Growth and Losses

bioAffinity develops non-invasive tests for early-stage lung cancer, mainly CyPath Lung, which analyzes sputum using flow cytometry and automated analysis, and it likewise runs laboratory services. The company noted CyPath Lung sales expanded more than 100% through the third quarter of 2026 compared with 2025, and it disclosed a Japan Patent allowance on October 8, a Hong Kong patent in September and a distribution Partnership with AvMEDICAL for veterans on September 30. Yet trailing revenue was approximately USD 5.90 million, down 23.2%, and the 2025 net loss was USD 14.91 million, up 64.9%. It regained Nasdaq compliance around September 9, 2026, after a period in which several volatility trading halts occurred.

Principal Risks and Upcoming Developments

Small diagnostic businesses often finance repeatedly, and each registered direct offering adds shares at a price that may sit below later trading. bioAffinity Technologies (NASDAQ:BIAF) lost USD 14.91 million in 2025 on revenue of USD 6.16 million, so the USD 4 million raise covers only part of a year of losses. Regulatory, reimbursement and adoption risks apply to CyPath Lung, and a Market Value in the single-digit millions leaves the stock vulnerable to delisting rules and substantial swings in price. Investors may wish to follow the closing and Warrant terms, third-quarter results, any further financing and Nasdaq compliance notices. A premarket decline on 13,667 the stock can change at the open.

Current Assessment

bioAffinity Technologies (NASDAQ:BIAF) is trading lower in premarket, and the best-supported cause is the October 8 financing of approximately USD 4 million at USD 6.122 per share, disclosed in a released headline list that should be independently confirmed against the filing. Taken together, the available evidence suggests that sales expansion and patent progress are being offset by recurring dilution and losses far above revenue. The next items to monitor are the closing specifics, third-quarter results and any new financing or listing notices.

FAQs

Q: What could explain bioAffinity falling 5.85% premarket?

A: The probable cause is the October 8, 2026 financing of approximately USD 4 million, with shares at USD 6.122, plus an 8.44% fall on October 8. bioAffinity Technologies (NASDA

Q: What does bioAffinity sell?

A: Its principal product is CyPath Lung, a non-invasive sputum test for early-stage lung cancer using flow cytometry and automated analysis, plus laboratory services. bioAffinity Technologies (NASDA

Q: How dilutive is a registered direct offering?

A: It sells new shares directly to market participants under an existing registration, so each deal adds to the share count. With a market value in the single-digit millions, even USD 4 million is substantial for bioAffinity Technologies (NASDA

Q: Which risks deserve the closest attention?

A: Recurring financing, losses far above revenue, reimbursement and adoption hurdles, and listing-standard pressure. bioAffinity Technologies (NASDA

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.